Page last updated: 2024-10-25

ciglitazone and Cancer of Pituitary

ciglitazone has been researched along with Cancer of Pituitary in 1 studies

ciglitazone: structure given in second source; PPAR agonist used for type II diabetes
ciglitazone : An aromatic ether that consists of 1,3-thiazolidine-2,4-dione with position 5 substituted by a 4-[(1-methylcyclohexyl)methoxy]benzyl group. A selective PPARgamma agonist.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Bogazzi, F1
Ultimieri, F1
Raggi, F1
Russo, D1
Vanacore, R1
Guida, C1
Viacava, P1
Cecchetti, D1
Acerbi, G1
Brogioni, S1
Cosci, C1
Gasperi, M1
Bartalena, L1
Martino, E1

Other Studies

1 other study available for ciglitazone and Cancer of Pituitary

ArticleYear
PPARgamma inhibits GH synthesis and secretion and increases apoptosis of pituitary GH-secreting adenomas.
    European journal of endocrinology, 2004, Volume: 150, Issue:6

    Topics: Adenoma; Animals; Annexin A5; Apoptosis; Cell Line; DNA Fragmentation; Female; Gene Expression; Huma

2004